adempas
(riociguat)Bayer HealthCare Pharmaceuticals Inc.
Usage: Adempas is indicated for adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or if inoperable, as well as for pulmonary arterial hypertension (PAH). It improves exercise capacity, WHO functional class, and delays clinical worsening. The drug is effective as monotherapy or in combination with other treatments.